270 related articles for article (PubMed ID: 33632218)
1. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG
BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218
[TBL] [Abstract][Full Text] [Related]
2. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of treating multidrug-resistant tuberculosis.
Resch SC; Salomon JA; Murray M; Weinstein MC
PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
[TBL] [Abstract][Full Text] [Related]
4. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
5. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
6. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine.
Fu H; Lewnard JA; Frost I; Laxminarayan R; Arinaminpathy N
Nat Commun; 2021 Jan; 12(1):424. PubMed ID: 33462224
[TBL] [Abstract][Full Text] [Related]
7. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
8. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
[TBL] [Abstract][Full Text] [Related]
9. Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis.
Weerasuriya CK; Harris RC; Quaife M; McQuaid CF; White RG; Gomez GB
Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33799544
[TBL] [Abstract][Full Text] [Related]
10. Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study.
Harris RC; Sumner T; Knight GM; Evans T; Cardenas V; Chen C; White RG
Lancet Glob Health; 2019 Feb; 7(2):e209-e218. PubMed ID: 30630775
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness, cost, and safety of four regimens recommended by WHO for RR/MDR-TB treatment: a cohort study in Eastern China.
Gu P; Lu P; Ding H; Liu Q; Ding X; Chen Y; Zhu L
Ann Med; 2024 Dec; 56(1):2344821. PubMed ID: 38697138
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
Alemayehu S; Yigezu A; Hailemariam D; Hailu A
PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
[TBL] [Abstract][Full Text] [Related]
13. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
15. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
16. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
Kendall EA; Shrestha S; Cohen T; Nuermberger E; Dooley KE; Gonzalez-Angulo L; Churchyard GJ; Nahid P; Rich ML; Bansbach C; Forissier T; Lienhardt C; Dowdy DW
PLoS Med; 2017 Jan; 14(1):e1002202. PubMed ID: 28045934
[TBL] [Abstract][Full Text] [Related]
17. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
[TBL] [Abstract][Full Text] [Related]
18. New Drugs and Vaccines for Tuberculosis.
Gaur PK; Mishra S
Recent Pat Antiinfect Drug Discov; 2017; 12(2):147-161. PubMed ID: 28990539
[TBL] [Abstract][Full Text] [Related]
19. Cross-sectional Whole-genome Sequencing and Epidemiological Study of Multidrug-resistant Mycobacterium tuberculosis in China.
Huang H; Ding N; Yang T; Li C; Jia X; Wang G; Zhong J; Zhang J; Jiang G; Wang S; Zong Z; Jing W; Zhao Y; Xu S; Chen F
Clin Infect Dis; 2019 Jul; 69(3):405-413. PubMed ID: 30321294
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
